Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Diagnostic
- Disease
- Cancer
- Genome
- DNA
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 280930
Licensor hereby grants to Licensee, under all Intellectual Property that (i) Licensor develops during the Term, and (ii) was developed by funding approved by the Joint Management Committee, a perpetual, royalty-free (except to the extent that royalties are owed to third party licensors, in which event such royalties shall be deducted by Licensor in determining COGS), worldwide, co-exclusive right with Licensor and license, with the right to grant sublicenses only as permitted under this agreement, to develop and use the Diagnostic Products in accordance with this Development Agreement. Such rights shall survive termination of this Development Agreement if Licensee is the Non-Defaulting Party.
Licensor hereby grants Licensee during the Term, a limited, royalty-free, non-exclusive right and license, with the right to grant sublicenses only as permitted under this agreement, to the use of certain of its trademarks and service marks, trade names and logos to be specifically identified by Licensor (collectively hereinafter referred to as “Licensor Marksâ€) solely in connection with the commercialization activities provided for in this Development Agreement.
Diagnostic Products shall mean any commercially available testing kit or service able to detect the Diagnostic Content as set forth Diagnostic Content
1. Myocardial infarction susceptibility – Leukotriene A4 Hydrolase (LTA4H) with estimated RR of 3.57 in African-Americans (estimated carrier frequencies of 20% in MI patients and 6% in the general population). These results are based on three independent African-American cohorts (the 'LTA4H Variants').
2. Type 2 diabetes susceptibility -TCF7L2 gene – estimated RR of 2.41 for those who are homozygous (15% of diabetics and 7% of the general population are homozygous). These results are based on three independent cohorts from US, Iceland and Denmark) (the 'TCF7L2 Variants').
3. Breast cancer susceptibility-BARDl breast cancer associated variants -one variant is carried by 6 to 7% of Icelandic patients compared to 3% of controls with overall RR of 1.8 and carriers have twice the risk for a second primary breast cancer. It also appears to increase penetrance of BRCA2 mutation carriers.
4. Any other potential targets arising from the molecular pathways associated with the above list, as listed in this agreement.
5. Any additional Diagnostic Content agreed to in writing by both Parties as an addendum
the gene-encoding leukotriene A4 hydrolase, linked to heart attack;
the gene-encoding transcription factor 7-like 2 (TCF7L2), linked to type 2 diabetes;
the gene encoding BARD1, linked to breast cancer.
IPSCIO Record ID: 280981
Licensor hereby grants to Licensee, under all Intellectual Property that (i) Licensor develops during the Term, and (ii) was developed by funding approved by the Joint Management Committee, a perpetual, royalty-free (except to the extent that royalties are owed to third party licensors, in which event such royalties shall be deducted by Licensor in determining COGS), worldwide, co-exclusive right with Licensor and license, with the right to grant sublicenses only as permitted under this agreement, to develop, make, have made, use, offer for sale, sell, have sold and import the Diagnostic Products.
Licensor hereby grants to Licensee during the Term, a limited, royalty-free, non-exclusive right and license, with the right to grant sublicenses only as permitted under this agreement, to access and use the Statistical/Informatics Programs, defined in agreement, that were developed by Licensor to define phase of haplotypes based on measured SNPs along with accuracy parameters, for use in the Development Effort.
Licensor hereby grants Licensee during the Term, a limited, royalty-free, non-exclusive right and license, with the right to grant sublicenses only as permitted under this agreement, to the use of certain of its trademarks and service marks, trade names and logos to be specifically identified by Licensor (collectively hereinafter referred to as “Licensor Marksâ€) solely in connection with the commercialization activities provided for in this Development Agreement. Licensee agrees to comply with Licensor’s guidelines delivered to Licensee from time to time with respect to manner of use, and to maintain the quality standards of Licensor with respect to the goods sold and services provided in connection with the Licensor Marks. Licensee recognizes and agrees that no ownership rights are vested or created by the limited rights of use granted to Licensee in connection with this use of the Licensor Marks, and that all goodwill associated with the use thereof inures to the benefit of Licensor.
Diagnostic Products shall mean any commercially available testing kit or service able to detect the Diagnostic Content as set forth Diagnostic Content
1. Myocardial infarction susceptibility – Leukotriene A4 Hydrolase (LTA4H) with estimated RR of 3.57 in African-Americans (estimated carrier frequencies of 20% in MI patients and 6% in the general population). These results are based on three independent African-American cohorts (the 'LTA4H Variants').
2. Type 2 diabetes susceptibility -TCF7L2 gene – estimated RR of 2.41 for those who are homozygous (15% of diabetics and 7% of the general population are homozygous). These results are based on three independent cohorts from US, Iceland and Denmark) (the 'TCF7L2 Variants').
3. Breast cancer susceptibility-BARDl breast cancer associated variants -one variant is carried by 6 to 7% of Icelandic patients compared to 3% of controls with overall RR of 1.8 and carriers have twice the risk for a second primary breast cancer. It also appears to increase penetrance of BRCA2 mutation carriers.
4. Any other potential targets arising from the molecular pathways associated with the above list.
5. Any additional Diagnostic Content agreed to in writing by both Parties as an addendum
SNP shall mean a single nucleotide polymorphism.
IPSCIO Record ID: 257479
— an exclusive, worldwide license under the BRCA2 Patent Applications and BRCA2 Patents to provide Diagnostic Services; and make, have made, use, offer for sale, and sell Diagnostic Products;
— an exclusive, worldwide license under the BRCA2 Patent Applications and BRCA2 Patents to make, have made, use, offer for sale, and sell Research Products;
— a non-exclusive, worldwide license under the BRCA2 Patent Applications, BRCA2 Patent and BRCA2 Information to undertake research on the BRCA2 Gene and BRCA2 Protein Product for the purposes of providing a Diagnostic Service or Diagnostic Product and/or Research Product; and,
— a non-exclusive, worldwide license under BRCA2 Information for the purposes of providing a Diagnostic Service and/or making a Diagnostic Product and/or making a Research Product to the extent that Licensee can demonstrate to the UK Licensors reasonable satisfaction that the BRCA2 Information in question is necessary to carry out the service or make the product.
Diagnostic Service a service for diagnosing susceptibility to breast cancer through determining
— the nucleotide sequence of the BRCA2 Gene in a sample of DNA from a test recipient and identifying any Mutations therein; and/or
— determining the presence or absence of BRCA2 Protein Product, either in whole or in part, from a sample from a test recipient.
Diagnostic Product a product, kit, instrument, toot reagent or material which has received regulatory approval in the country of use or sale, and/ or which is being used or sold by Licensee, its Sub-licensees or Affiliates or their customers for the clinical analysis of the BRCA2 Gene or BRCA2 Protein Product for the purposes of determining any Mutations therein.
The patent is Materials and Methods Relating to the Identification and Sequencing of the BRCA2 Cancer Susceptibility Gene and Uses Thereof.
IPSCIO Record ID: 209521
Licensor grants a worldwide, nonexclusive license, with no right to grant sublicenses, under Licensor Alliance Patent Rights and Licensor’s Deliverable Alliance Technology solely to the extent necessary to permit Licensee and its Affiliates to Commercialize Non-Alliance Products.
Licensor grants a worldwide, nonexclusive license, with no right to grant sublicenses, under Licensor Independent Patent Rights and under Independent Technology that was previously used by Licensee or its Affiliates in Commercialization of an Alliance Product, solely to the extent necessary to permit Licensee and its Affiliates to Commercialize Non-Alliance Products that had been subject to rejected NPCDs (New Product Concept Document) in the Conditionally Exclusive Areas.
For Outside the Alliance Field, for products, other than therapeutic products, Licensor grants a nonexclusive license under Licensor’s Deliverable Alliance Technology and any Licensors Alliance Patent Rights, to manufacture, use, sale, offer for sale or import of which is covered by a Valid Claim of the Licensors Alliance Patent Rights
The Licensor grants licenses of the scope granted under the corresponding Independent Technology and Alliance Technology Copyrighted Works that are part of Joint Alliance Technology.
Copyrighted Works means original works of authorship, including, without limitation, computer programs (in source code, object code or other form), notes, sketches, drawings and reports.
